Literature DB >> 24657093

Structure-guided analysis of the human APOBEC3-HIV restrictome.

Halil Aydin1, Matthew W Taylor1, Jeffrey E Lee2.   

Abstract

Human APOBEC3 (A3) proteins are host-encoded intrinsic restriction factors that inhibit the replication of many retroviral pathogens. Restriction is believed to occur as a result of the DNA cytosine deaminase activity of the A3 proteins; this activity converts cytosines into uracils in single-stranded DNA retroviral replication intermediates. A3 proteins are also equipped with deamination-independent means to restrict retroviruses that work cooperatively with deamination-dependent restriction pathways. A3 proteins substantially bolster the intrinsic immune system by providing a powerful block to the transmission of retroviral pathogens; however, most retroviruses are able to subvert this replicative restriction in their natural host. HIV-1, for instance, evades A3 proteins through the activity of its accessory protein Vif. Here, we summarize data from recent A3 structural and functional studies to provide perspectives into the interactions between cellular A3 proteins and HIV-1 macromolecules throughout the viral replication cycle.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24657093     DOI: 10.1016/j.str.2014.02.011

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  45 in total

1.  Structural Insights into HIV-1 Vif-APOBEC3F Interaction.

Authors:  Masaaki Nakashima; Hirotaka Ode; Takashi Kawamura; Shingo Kitamura; Yuriko Naganawa; Hiroaki Awazu; Shinya Tsuzuki; Kazuhiro Matsuoka; Michiko Nemoto; Atsuko Hachiya; Wataru Sugiura; Yoshiyuki Yokomaku; Nobuhisa Watanabe; Yasumasa Iwatani
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

2.  Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.

Authors:  Erez Pery; Ann Sheehy; N Miranda Nebane; Andrew Jay Brazier; Vikas Misra; Kottampatty S Rajendran; Sara J Buhrlage; Marie K Mankowski; Lynn Rasmussen; E Lucile White; Roger G Ptak; Dana Gabuzda
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

Review 3.  HIV suppression by host restriction factors and viral immune evasion.

Authors:  Xiaofei Jia; Qi Zhao; Yong Xiong
Journal:  Curr Opin Struct Biol       Date:  2015-05-16       Impact factor: 6.809

Review 4.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

Review 5.  Structural insights for HIV-1 therapeutic strategies targeting Vif.

Authors:  Jason D Salter; Guillermo A Morales; Harold C Smith
Journal:  Trends Biochem Sci       Date:  2014-08-12       Impact factor: 13.807

6.  Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif.

Authors:  Tayyba T Baig; Yuqing Feng; Linda Chelico
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

7.  Determinants of Oligonucleotide Selectivity of APOBEC3B.

Authors:  Jeffrey R Wagner; Özlem Demir; Michael A Carpenter; Hideki Aihara; Daniel A Harki; Reuben S Harris; Rommie E Amaro
Journal:  J Chem Inf Model       Date:  2018-09-10       Impact factor: 4.956

8.  The in vitro Biochemical Characterization of an HIV-1 Restriction Factor APOBEC3F: Importance of Loop 7 on Both CD1 and CD2 for DNA Binding and Deamination.

Authors:  Qihan Chen; Xiao Xiao; Aaron Wolfe; Xiaojiang S Chen
Journal:  J Mol Biol       Date:  2016-04-08       Impact factor: 5.469

Review 9.  Functions and Malfunctions of Mammalian DNA-Cytosine Deaminases.

Authors:  Sachini U Siriwardena; Kang Chen; Ashok S Bhagwat
Journal:  Chem Rev       Date:  2016-09-01       Impact factor: 60.622

10.  Characterization of the Catalytic Domain of Human APOBEC3B and the Critical Structural Role for a Conserved Methionine.

Authors:  Sachini U Siriwardena; Thisari A Guruge; Ashok S Bhagwat
Journal:  J Mol Biol       Date:  2015-08-14       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.